

L'utilità del disordine: approcci biotecnologici allo studio delle proteine intrinsecamente disordinate


Prof. Maria Luisa Tutino,
Ph.D.

Dept. Chemical Sciences –Federico II
University Naples Italy
tutino@unina.it




Struttura delle proteine: vecchi e nuovi concetti

Structured domain




structure-function paradigm
(established)

Disordered region




disorder-function paradigm
(emerging)



NMR as a tool to observe disorder

To perform and analyze NMR experiments that provide information on protein flexibility in terms of *conformational ensembles*.

Single domain




JACS 2011

Angew Chem 2011

JCTC 2013


Nat Commun 2014

Multidomain



PLoS CB 2014

Disordered



JACS 2010

PNAS 2013

BJ 2013a, 2013b


Disorder Becomes Apparent

▶ Early discovery

- ▶ Bovine serum albumin binding sites (Karush, 1950)


▶ Later...

- ▶ Rapid rise of genomic data (~1990)
 - ▶ **P**redictors **of** **n**atural **d**isordered **r**egions (PONDRs)
- ▶ Early proton NMR experiments (Daniels et al, 1978)



Disorder, Disorder, (most)Everywhere!

- ▶ Generally:
 - ▶ ↑ complexity of organism → ↑ disorder
 - ▶ Some exceptions
- ▶ **35–51%** of eukaryotic proteome (Dunker et al, 2000)



Hosoda et al, 2011


Why Did We Miss It?

► Unobserved

- Bias of experiment
- Access to genomic data limited before ~1990
- Crystal structure relatively uninformative

► Ignored

- Crystal structure artifacts dismissed
- Disorder thought to be an artifact



What is Disorder in Proteins?

- ▶ **Definition:**

- ▶ A protein that does not adopt a well-defined native structure when isolated in solution under near-physiological conditions (Eliezer, 2009)

- ▶ **2 types**

- ▶ Denatured state ensembles (DSEs)
- ▶ Intrinsically disordered proteins (IDPs)


- ▶ **Vast and malleable configurational ensembles (CEs)**

- ▶ **Charged**


- ▶ **What can impact disorder?**

Proposed Mechanisms

- ▶ Regulation
 - ▶ Folding upon binding
 - ▶ Highly specific / low affinity binding
- ▶ Multiple interaction sites
- ▶ Aggregation




Schärfp et al, 2001




Nature Reviews | Molecular Cell Biology
Dyson & Wright, 2005

Structured domain




structure-function paradigm
(established)




High affinity + high
specificity

Disordered region




disorder-function paradigm
(emerging)



Low affinity + high
specificity


Why has evolution favoured intrinsic disorder



Zhou H-X *TIBS* 2011

One intriguing proposal is that intrinsic disorder makes low affinity compatible with high specificity.

Why has evolution favoured intrinsic disorder



Zhou H-X *TIBS* 2011

This is because in many scenarios it is desirable that protein protein interactions are of low affinity e.g. in signaling.



Why are IDPs Interesting?

Diverse Roles!

- ▶ Regulatory
 - ▶ Homeostasis of signaling pathways
 - ▶ Translation/Transcription
- ▶ Structural
 - ▶ Flexible Linkers

AND..... They can kill you.


- ▶ Disease states
 - ▶ Cancer (lack of cell cycle regulation)
 - ▶ Brain (amyloid plaque formation)



Lee et al, 2003

facciamo un esempio...

Una proteina umana IDPR coinvolta in una malattia genetica ultrarara: CDKL5



Mutazioni in CDKL5 determinano una encefalopatia epilettica ad esordio precoce (CDD)

1: circa 50.000 bambine (*X-linked*)
Ritardo mentale grave
Incapacità di usare le mani (stereotipie)
Epilessia farmaco resistente!


CDKL5 Protein Replacement Therapy (PRT) rescues neurological phenotypes of a mouse model of CDKL5 disorder*

- TAT -> N-terminal tag with the ability to deliver macromolecules and proteins into cells and into the brain
- When administered as intracerebroventricular infusion (ICV) or systemically (EV), TAT-CDKL5_1 restored hippocampal development, hippocampus-dependent memory and breathing pattern, rescuing various neuroanatomical and behavioral defects in Cdkl5-null mice.

**TATk28-CDKL5 protein therapy as promising clinical tool
for the treatment of CDKL5 deficiency disorder!**

**WE NEED TO PRODUCE LARGE QUANTITIES OF
RECOMBINANT CDKL5**

CDKL5 is a difficult protein to be produced




* Kilstrup-Nielsen C, *et al.*, Neural Plast. 2012:728267

Recombinant CDKL5 production in bacterial cell factories

Production of TAT-CDKL5_5 at suboptimal growth temp in rich media (growth at 20°C, induction at 0,7 OD_{600nm} 100 µM IPTG, downshift at 15°C, 18 hrs induction)

The protein is **heavily proteolysed and accumulates as insoluble inclusion bodies** even at lower production temperature.




Anti-His Tag Ab

Pseudoalteromonas haloplanktis TAC125

E. coli BL21(DE3)

PhTAC125 soluble extracts
0°C 15°C



Anti-CDKL5 N-term Ab

Production of TAT-CDKL5_5 in synthetic medium at two growth temp (0 and 15°C) (induction at 0,7 OD_{600nm} 10mM galactose, different induction times)

The protein is **fully soluble and largely preserved from proteolysis** at both production temperatures!

THE PSYCHROPHILIC CELL FACTORY...

Pseudoalteromonas haloplanktis TAC125



- ✓ Gram negative, gamma proteobacterium, from Antarctic sea water
- ✓ Full genome knowledge¹
- ✓ Growth in a wide range of temperatures (-5/25°C)
- ✓ Growth at high cell density in flasks or automatic fermentors
- ✓ Short replication time in complex media
- ✓ Medium copy number cryptic plasmid pMtBL²




✓ **Established gene-expression technology³**

(1) Médigue et al. (2005), *Genome Research*, 15: 1325-35; (2) Tutino et al. 2001 *Extremophiles* (2001) 5, 257-264


(3) Parrilli et al., (2008) in *Psychrophiles: from Biodiversity to Biotechnology* Margesin, R. et al. (Eds.) Springer-Verlag pp.365-379



High quality rechCDKL5_1 is produced by *PhTAC125*




Is the recombinant enzyme active??




Rec *hCDKL5_1* produced in *PhTAC125* is active!!

In vivo co-expression activity assay



hEB2 and *hCDKL5_1* are co-expressed in *PhTAC125* under the control of the same promoter at 15°C



EB2 is phosphorylated in *PhTAC125* only when co-expressed with CDKL5 WT

This approach will be used to preliminary characterize if the missense mutations may alter CDKL5 activity on EB2!

Conclusioni:

- Il disordine è molto diffuso nel proteoma umano
- Nuove metodiche per studiare le IDP
- Nuovi approcci biotecnologici per la produzione di IDP per motivi di studio e di terapia
 - *P. haloplanktis* TAC125 come ospite innovativo per la produzione ricombinante di IDP (tecnologia *made in Naples*)